Co-Diagnostics Inc.
(NASDAQ:CODX), a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt.
Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility.
The distribution was initiated at the behest of the India Center for Cellular and Molecular Platforms (C-CAMP), an initiative backed by the India Department of Biotechnology.
Expanding Point-Of-Care Diagnostics For Virus Testing Alongside deploying these test kits, the company completed a proof-of-concept trial for a new extraction-free Ebola diagnostic tool.
